GOLGANCIO Trademark

Trademark Overview


On Wednesday, July 10, 2024, a trademark application was filed for GOLGANCIO with the United States Patent and Trademark Office. The USPTO has given the GOLGANCIO trademark a serial number of 98641582. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Monday, June 2, 2025. This trademark is owned by Celgene Corporation. The GOLGANCIO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.
golgancio

General Information


Serial Number98641582
Word MarkGOLGANCIO
Filing DateWednesday, July 10, 2024
Status680 - APPROVED FOR PUBLICATION
Status DateMonday, June 2, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, July 10, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Trademark Events


Event DateEvent Description
Wednesday, July 10, 2024NEW APPLICATION ENTERED
Sunday, February 2, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 3, 2025NON-FINAL ACTION E-MAILED
Monday, February 3, 2025ASSIGNED TO EXAMINER
Monday, February 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 3, 2025NON-FINAL ACTION WRITTEN
Monday, May 5, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 5, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 5, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 7, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, May 7, 2025FINAL REFUSAL WRITTEN
Wednesday, May 7, 2025FINAL REFUSAL E-MAILED
Friday, May 30, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Friday, May 30, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 2, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, May 30, 2025TEAS/EMAIL CORRESPONDENCE ENTERED